APO-GRANISETRON granisetron hydrochloride 3mg/3mL injection ampoule

Country: Ավստրալիա

language: անգլերեն

source: Department of Health (Therapeutic Goods Administration)

active_ingredient:

granisetron hydrochloride, Quantity: 3.36 mg (Equivalent: granisetron, Qty 3 mg)

MAH:

Arrotex Pharmaceuticals Pty Ltd

INN:

granisetron hydrochloride

pharmaceutical_form:

Injection

composition:

Excipient Ingredients: citric acid monohydrate; hydrochloric acid; sodium hydroxide; sodium chloride; water for injections

administration_route:

Intravenous

units_in_package:

5

prescription_type:

(S4) Prescription Only Medicine

therapeutic_indication:

Adults: Granisetron Injection is indicated for use in adults for:,The prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy;,The prevention of nausea and vomiting induced by radiotherapy.,Granisetron Injection is also indicated for use in the prevention and treatment of post-operative nausea and vomiting.,Children: Granisetron injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

leaflet_short:

Visual Identification: Granisetron Hydrochloride Injection, 3mg/3mL is a clear and colorless solution, in a type 1 glass ampoule; Container Type: Ampoule; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

authorization_status:

Registered

authorization_date:

2014-12-17